This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

RACING - long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

  • a multicenter, open-label trial shows that moderate-intensity statin with ezetimibe combination therapy is non-inferior to high-intensity statin monotherapy in patients with ASCVD (atherosclerotic cardiovascular disease) in the long term
    • a multicenter, open-label, non-inferiority trial in 26 hospitals in South Korea
      • patients aged 19-80 years with ASCVD (n=3780) were randomized to moderate-intensity statin (rosuvastatin 10 mg once daily) with ezetimibe (10 mg once daily) combination therapy or high-intensity statin (rosuvastatin 20 mg once daily) monotherapy
        • randomization was stratified by LDL-c concentration (< 100 mg/dL) and presence of diabetes at baseline
        • ASCVD was defined as the presence or occurrence of myocardial infarction, acute coronary syndrome, coronary revascularization or other arterial revascularization, ischemic stroke, or PAD (peripheral arterial disease)
        • patients with active liver disease or a life expectancy <3 years, donor organ recipients, and pregnant or lactating women were excluded from participation
        • atients were followed up for 3 years
    • within 3 years, the primary outcome, which was a composite of cardiovascular death, major cardiovascular events, and non-fatal stroke, occurred equally often in both groups
    • in the combination therapy group, the percentage of patients with an LDL-c concentration < 70 mg/dL was higher and the percentage of patients in whom treatment had to be discontinued or the dose reduced was lower than in the monotherapy group.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.